WASHINGTON — The Trump administration wants to modernize the federal guidelines for companies that sell made-to-order DNA in hopes of keeping dangerous genetic material — like smallpox or the Ebola virus — out of the hands of malicious potential customers, federal officials confirmed to STAT this week.

The administration’s work is still in early stages, and it’s too soon to tell whether or how the government will make the guidelines more stringent, as companies and experts in the space have called for. Right now, the Department of Health and Human Services is kicking off “a broad interagency effort to review the guidance and make any necessary changes to reflect the evolving technological landscape,” said Theresa Lawrence, a director in HHS’s Office of the Assistant Secretary for Preparedness and Response.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy